Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13993956 | 1.00 | ALDH1A1 (0.64) | ALDH1A1MAPTPOLBL3MBTL1CYP1A2 | |
| Hydrochloric Acid SCHEMBL29360031 | 0.98 | ALDH1A1 (0.61) | ALDH1A1MAPTPOLBL3MBTL1CYP1A2 | |
| SCHEMBL11880993 | 0.98 | ALDH1A1 (0.60) | ALDH1A1MAPTPOLBL3MBTL1CYP1A2 | |
| SCHEMBL13993971 | 0.93 | — | — | |
| Succinic Acid SCHEMBL11313801 | 0.92 | CYP1A2 (0.62) | ALDH1A1MAPTPOLBL3MBTL1CYP1A2 | |
| SCHEMBL23344402 | 0.87 | — | — | |
| SCHEMBL12602739 | 0.87 | PAOX (0.59) | ALDH1A1MAPTPOLBL3MBTL1CYP1A2 | |
| SCHEMBL279742 | 0.86 | CYP1A2 (0.67) | ALDH1A1MAPTPOLBL3MBTL1CYP1A2 | |
| Hydrochloric Acid SCHEMBL11824629 | 0.85 | CYP1A2 (0.64) | ALDH1A1MAPTPOLBL3MBTL1CYP1A2 | |
| SCHEMBL12522442 | 0.85 | PAOX (0.69) | ALDH1A1MAPTPOLBL3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102095808-B | Analysis method of related substances in Ebastine | CHONGQING HUAPONT PHARM CO LTD | 2014-04-02 | — | — | CN | claimed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| EP-3377484-B1 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023142600-A1 | AMINO LIPID, PREPARATION METHOD THEREFOR, AND USE THEREOF | 深圳虹信生物科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| EP-4215188-A1 | AN AMINO LIPID, PREPARATION METHOD AND APPLICATION THEREOF | Shenzhen MagicRNA Biotechnology Co., Ltd. (CN) | 2023-07-26 | — | — | EP | disclosed |
| EP-2718270-B1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2022-04-27 | — | — | EP | disclosed |
| WO-2022006439-A2 | COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20210244736-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2021-08-12 | — | — | US | disclosed |
| EP-3305900-B1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2021-07-21 | — | — | EP | disclosed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2005012256-A1 | 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| EP-0883613-A1 | SULFONAMIDE DERIVATIVES AS 5HT7 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-12-16 | — | — | EP | disclosed |
| WO-1997029097-A1 | SULFONAMIDE DERIVATIVES AS 5HT7 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-08-14 | — | — | WO | disclosed |
| US-4316903-A | BACTERICIDES AND FUNGICIDES | MERCK & CO., INC. (US) | 1982-02-23 | — | — | US | disclosed |
| US-4273781-A | Treatment of pain, fever, and inflammation with compositions containing piperidinobutan-and 3-buten-2-ones | MERCK & CO., INC. (US) | 1981-06-16 | — | — | US | disclosed |
| US-4250184-A | ANTIARTHRITIC AGENTS; SKIN DISORDERS; GOUT; RHEUMATIC DISEASES | MERCK & CO., INC. (US) | 1981-02-10 | — | — | US | disclosed |
| US-4145426-A | FUNGICIDES, BACTERICIDES | MERCK & CO., INC. (US) | 1979-03-20 | — | — | US | disclosed |
| US-4035395-A | Process for the preparation of ketones | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-12 | — | — | US | disclosed |
| US-4014889-A | Process for preparing ketones | BAYER AKTIENGESELLSCHAFT (DT) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | ALDH1A1 145/4885MAPT 21/4885POLB 930/4885 |
| US-20210244736-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | ALDH1A1 3107/4885MAPT 4746/4885POLB 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.